Quarterly Report Q2 2018

August 16, 2018

An Overview of the Prometic Quarterly Report

  • Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)
  • Submitted plan to FDA regarding filing of the amended BLA for RyplazimTM (plasminogen)
  • Q2 revenues of $20.2 million, and net loss of $33.1 million. R&D and Admin costs down from the same period in 2017.
  • Received Rare Pediatric Disease Designation for PBI-4050 from the FDA for the treatment of Alström Syndrome
  • Presented new clinical data for PBI-4050 and PBI-4547 in liver fibrosis and for IVIG in PIDD demonstrating signs of positive clinical activity at several scientific conferences
Previous Flipbook
Quarterly Report 2018 Q3
Quarterly Report 2018 Q3

Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manuf...

Next Flipbook
Quarterly Report Q1 2018
Quarterly Report Q1 2018

Prometic reports its 2018 first quarter highlights and financial results